Ann: Trading Halt, page-6

Street Talk
Canaccord, Wilsons on board for ImpediMed raise
Anthony Macdonald, Yolanda Redrup and Kanika Sood
Oct 25, 2021 – 10.42am
Save
Share
Stockbrokers Canaccord and Wilsons are on board as joint lead managers for biotech company ImpediMed’s latest capital raising.

Bankers from the firms have been prepping investors for the raise, which is due to launch on Monday morning.


ASX-listed stock ImpediMed is raising capital on Monday. Istock

The medical device company makes a product that aids in the early detection of secondary lymphedema, provides fluid status for patients living with heart failure and allows measurement and tracking of various body composition parameter.

The capital raise, details of which are imminent, follows a $25 million raise in March 2020. At the time the company was trading at 4¢ per share, but its last traded price was 17¢, giving the business a market capitalisation of $247 million.

Last week ImpediMed completed it lymphoedema prevention trial, meeting its primary end point, and demonstrating that intervention in patients using the company’s L-Dex technology resulted in a lower rate of progression to chronic lymphodema, compared to patients with early detection using a tape measure.

About 92 per cent of patients using ImpediMed’s device did not progress to chronic disease